Jeffrey Sosman Archives
Investigators find clues to melanoma treatment resistance
Oct. 29, 2015—Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.
Bradfords’ strong support bolsters melanoma research
Sep. 25, 2014—When something attacks you, you want to attack it back. That’s how Lillian “Tooty” Bradford views her late husband James “Jimmy” Bradford Jr.’s decision to make an initial gift to fund melanoma research at Vanderbilt-Ingram Cancer Center (VICC).
VICC researchers in spotlight at national cancer conference
Jun. 19, 2014—New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.
VU study identifies new gene fusions in melanoma
Dec. 19, 2013—Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer.
Sosman to lead national melanoma research team
Dec. 12, 2013—Jeffrey Sosman, M.D., professor of Medicine and leader of the Vanderbilt Melanoma Program, will head one of two teams of researchers at prominent national institutions investigating acral melanoma, a skin cancer that typically forms on the hands, soles of the feet or under the fingernails.
Sosman named one of ‘hottest’ researchers in U.S.
Sep. 26, 2013—Jeffrey Sosman, M.D., professor of Medicine, Ingram Chair for Cancer Research and director of the Vanderbilt Melanoma Program, was named one of the Hottest Scientific Researchers of the last year by Thomas Reuters Science Watch.
2013 Academic Enterprise Faculty Awards
May. 23, 2013—The 2013 Vanderbilt University Medical Center Academic Enterprise Faculty Awards, which were presented during Wednesday’s Spring Faculty meeting, included awards for Excellence in Teaching and Outstanding Contributions to Research. Award recipients were nominated by their faculty colleagues and chosen by the Academic Enterprise Faculty Awards Selection Committee.
Foundation lauds graduate student’s melanoma research
Mar. 28, 2013—Katherine Hutchinson, a third-year graduate student in Cancer Biology at Vanderbilt University, has won a $10,000 Research Scholar Award from the Joanna M. Nicolay Melanoma Foundation.
Combined drug therapy may delay melanoma progression
Oct. 25, 2012—Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene.
Stand Up to Cancer TV broadcast airs Sept. 7
Aug. 30, 2012—Stand Up To Cancer (SU2C), the nonprofit organization that helps fund various Vanderbilt-Ingram Cancer Center (VICC) investigators, returns to prime time television for its third broadcast Friday, Sept. 7, at 7 p.m. The hourlong show featuring Hollywood celebrities, recording artists and sports figures will include special performances and a celebrity phone/multi-media bank that will allow...
Study finds mutation in melanoma sensitive to drug
Jul. 26, 2012—An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.
New cancer drug shows promise in early testing
Jul. 12, 2012—An experimental drug that activates T-cells and promotes an immune response to fight tumors has shown promising early results in patients with kidney cancer, melanoma and non-small cell lung cancer. Vanderbilt-Ingram Cancer Center investigators Leora Horn, M.D., Jeffrey Sosman, M.D., and researchers from several other cancer centers tested the new compound. The results of the...
